Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-07 |
2024-03 |
-6.06 |
N/A |
N/A |
N/A |
2024-02-28 |
2023-12 |
-5.32 |
-5.68 |
-0.36 |
-6.77% |
2023-11-06 |
2023-09 |
-4.78 |
-5.34 |
-0.56 |
-11.72% |
2023-08-08 |
2023-06 |
-4.47 |
-4.69 |
-0.22 |
-4.92% |
2023-05-09 |
2023-03 |
-4.98 |
-4.23 |
0.75 |
15.06% |
2023-02-23 |
2022-12 |
-4.41 |
-4.98 |
-0.57 |
-12.93% |
Date |
Firm |
Action |
From |
To |
2023-09-18 |
Evercore ISI Group |
Upgrade |
Outperform |
Outperform |
2023-09-13 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-09-11 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-09-10 |
B. Riley Securities |
Upgrade |
Neutral |
Neutral |
2023-09-04 |
B. Riley Securities |
Upgrade |
Neutral |
Neutral |
2023-08-08 |
Oppenheimer |
Upgrade |
Outperform |
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2024-04-01 |
BATE KENNETH M |
Director |
1.20K |
Sale |
2024-04-01 |
DALY JAMES M. |
Director |
1.20K |
Sale |
2024-04-07 |
FRIEDMAN PAUL A |
Director |
841.28K |
Sale |
2024-01-22 |
HOWARTH ALEX G |
Chief Financial Officer |
18.74K |
Stock Award(Grant) |
2024-01-22 |
HUNTSMAN CAROLE |
Officer |
11.47K |
Stock Award(Grant) |
2024-03-31 |
LEVY RICHARD S |
Director |
10.30K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Baker Brothers Advisors, LLC |
1.55M |
356.92M |
8.36% |
2023-06-29 |
Avoro Capital Advisors LLC |
1.52M |
350.00M |
8.20% |
2023-06-29 |
Janus Henderson Group PLC |
1.48M |
342.83M |
8.03% |
2023-06-29 |
Vanguard Group Inc |
1.47M |
338.54M |
7.93% |
2023-06-29 |
Blackrock Inc. |
1.04M |
241.06M |
5.65% |
2023-06-29 |
State Street Corporation |
543.76K |
125.61M |
2.94% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
453.15K |
104.68M |
2.45% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
377.69K |
87.25M |
2.04% |
2023-06-29 |
Janus Henderson Contrarian Fund |
324.94K |
75.06M |
1.76% |
2023-08-30 |
iShares Russell 2000 ETF |
310.57K |
55.90M |
1.68% |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
263.58K |
47.44M |
1.43% |
2023-06-29 |
Vanguard Small Cap Value Index Fund |
261.54K |
60.42M |
1.42% |
Split |
Date |
1 : 35 |
2016-07-25 |